AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00696618
Drug: Fleet Enema
RxNorm normalized name: Fleet Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyper-osmolar preparation
Trial: NCT02614118
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
Trial: NCT02614118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 45 minutes before root canal treatment
Trial: NCT02493933
Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02225093
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02511639
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
Trial: NCT00156117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03800667
Drug: Ascorbic Acid 1000 MG
RxNorm normalized name: ascorbic acid 1000 MG
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
Trial: NCT01646775
Drug: epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: withold epidural fentanyl
Trial: NCT02832037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01188811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
Trial: NCT00623506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)
Trial: NCT00422019
Drug: AMG 102 at 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
Trial: NCT03646123
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 by IV infusion
Trial: NCT04353037
Drug: Group 1 HCQ
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled participants randomized in Group 1 receive the HCQ drug
Trial: NCT04353037
Drug: Group 2 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled participants randomized in Group 2 will receive a placebo drug
Trial: NCT01718119
Drug: r-hCG
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hCG(250mcg) injection subcutaneously
Trial: NCT00006369
Drug: ERA-923
RxNorm normalized name: ALCOHOL 4 mL TOPICAL CLOTH [Bioserica ERA Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02023554
Drug: Theophylline with azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7.
Trial: NCT02023554
Drug: Theophylline alone
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
Trial: NCT00638495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is to be administered orally once daily, after supper in principle, for 28 days.
Trial: NCT00141830
Drug: Methotrexate plus ERB-041 for 12 weeks
RxNorm normalized name: methotrexate 2.5 MG (12) (7.5 MG per Week) Oral Tablet Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00141830
Drug: Placebo for 12 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00872417
Drug: first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
Trial: NCT00872417
Drug: second line ARV therapy (3TC+TDF+LPV/RTV)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
Trial: NCT02595398
Drug: Sham Procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sham procedure administered at 2 timepoints
Trial: NCT01460342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
Trial: NCT01844141
Drug: 70% alcohol - 0.5% clorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
Trial: NCT02435199
Drug: EMA401 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02435199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01689519
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied as tablets
Trial: NCT01867762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
Trial: NCT03692949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03692949
Drug: LY3451838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose administered SC
Trial: NCT00744393
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
Trial: NCT02247258
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm/group descriptions
Trial: NCT01987102
Drug: [6R] 5,10-methylenetetrahydrofolate (arfolitixorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients will be treated according to the MAP schedule and will receive the study drug \[6R\] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and \[6R\] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) \[6R\] 5,10-methylenetetrahydrofolate® dose cohort groups: with \[6R\] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort.
Trial: NCT02247258
Drug: Azathioprine in case of endoscopic recurrence
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm/group descriptions
Trial: NCT00758602
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to center's practice
Trial: NCT02425254
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg intravenous solution for infusion
Trial: NCT02425254
Drug: Intravenous saline 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride in order to ensure double-blinding
Trial: NCT03987451
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide placebo s.c. given once-weekly for 48 weeks
Trial: NCT01154738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00
Trial: NCT02625389
Drug: Lipiodol® Ultra Fluid with surgical glues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
Trial: NCT03632668
Drug: AD-2072 80/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-2072 80/5mg tablet
Trial: NCT03632668
Drug: AD-2071 10/20mg + AD2072 80/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-2071 10/20 mg + AD-2072 80/5mg tablet
Trial: NCT01543854
Drug: RLX030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of RLX030 over 20 hrs
Trial: NCT01543854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of placebo over 20 hours
Trial: NCT04489368
Drug: Neo-Adjuvant Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-Adjuvant Chemotherapy, delivered concurrently with Neo-Adjuvant Radiotherapy.
Trial: NCT00756743
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules q12 hours for 10 days
Trial: NCT03465345
Drug: Oligomeric Procyanidin Complex
RxNorm normalized name: procyanidin A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
Trial: NCT03259919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
Trial: NCT01872819
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 1 of 160 possible interventions
Trial: NCT03050307
Drug: TAK-438 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets
Trial: NCT03050307
Drug: Bismuth-Containing Quadruple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Trial: NCT01560104
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00653068
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02488252
Drug: Semi-individualised Chinese Medicine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb
Trial: NCT02488252
Drug: Routine medical care (active comparator)
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
Trial: NCT00653068
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT00653068
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00430027
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given 650 mg/m\^2 BID on days of ration therapy, 825 mg/m\^2 day 1-14, day 15-20 off x 4
Trial: NCT02895100
Drug: PTG-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of PTG-100 by subject for a 12 week treatment period.
Trial: NCT02895100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of Placebo capsules by subject for a 12 week treatment period.
Trial: NCT00269295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
Trial: NCT00125229
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02535143
Drug: Taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
Trial: NCT00003282
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02750488
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
Trial: NCT04030026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo tablet (matching NAL ER BID) over a 3 week period.
Trial: NCT01187485
Drug: Androderm® 2.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Trial: NCT01187485
Drug: Androderm® 5.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Trial: NCT00202969
Drug: S-1 plus CDDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
Trial: NCT02959658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured to mimic Dimethyl Fumarate capsules
Trial: NCT00414648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo dose of 2 tablets per day for 1 year.
Trial: NCT01187485
Drug: Androderm® 7.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
Trial: NCT02045719
Drug: uncaria tomentosa (cat´s claw)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03414736
Drug: SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous
Trial: NCT00001384
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01235949
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
Trial: NCT00215345
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01056835
Drug: prostaglandin I2 analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00733473
Drug: % 0.9 Saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
Trial: NCT03201419
Drug: Placebo oral solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured to mimic experimental drug
Trial: NCT03201419
Drug: Placebo ODT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufactured to mimic experimental drug
Trial: NCT01670721
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Trial: NCT01670721
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
Trial: NCT00880100
Drug: Ultrase® MT12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
Trial: NCT02313584
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01431521
Drug: MK-4074 200 mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
Trial: NCT01431521
Drug: Placebo for MK-4074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100-mg capsules, orally, BID for 4 weeks.
Trial: NCT00486512
Drug: 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
RxNorm normalized name: calcium carbonate 1250 MG
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00486512
Drug: placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)
RxNorm normalized name: calcium carbonate 1250 MG
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01921283
Drug: no- BIS sensor attachment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01867502
Drug: MET + Glibenclamide Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator.
Trial: NCT00439296
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Treatment Course 1 only:~• 60 mg/m2/day IV over 15 minutes on day 1.
Trial: NCT02389218
Drug: sequential drug adjustment (propafenone, sotalol or flecainide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
Trial: NCT00439296
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Treatment Course 1:~• Given Intrathecally on day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 2:~• Given Intrathecally on day 1, 8, 15 and 22 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age~In Treatment Course 3:~Intrathecally on day 1 at the age-defined dose
Trial: NCT00439296
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Course 2 only: • 1000mg/m2/day IV over 30 minutes to be given on day 1.